Scan Science and Technology
Contact Leading Edge Experts & Companies
The Experts below are selected from a list of 405 Experts worldwide ranked by ideXlab platform
Pierre Youinou – One of the best experts on this subject based on the ideXlab platform.
Outcome of early monoarthritis: a followup study.The Journal of rheumatology, 2007Co-Authors: Aymeric Binard, Jean-marie Berthelot, Valérie Devauchelle-pensec, Seydou Alassane, Sandrine Jousse-joulin, Gérard Chalès, Catherine Le Henaff, Jean B Thorel, Sylvie Hoang, Pierre YouinouAbstract:
OBJECTIVE: To evaluate clinical, laboratory, and radiological features and outcomes in patients with monoarthritis (MA), identified in a cohort of patients with early arthritis. METHODS: A cohort of 270 patients with undiagnosed arthritis of less than 1 year9s duration was divided into 3 groups: single episode of MA (MA, n = 27), MA with a history of patient-reported arthritis (MA + past, n = 23), and oligo- or polyarthritis (OA/PA, n = 220). At 6-month intervals, all patients underwent a standardized examination, radiographs, and standard laboratory tests including rheumatoid Factors (RF), Antiperinuclear Factor (APF), antikeratin antibody (AKA), anticyclic citrullinated peptide antibody (anti-CCP), antinuclear antibodies, and HLA-AB-DR typing. After a median followup of 30 months, the diagnosis was evaluated by a hospital-based rheumatologist. RESULTS: Age and sex did not differ across the 3 groups. Knee involvement was more common in the MA group than in the MA + past group (p
Antiperinuclear Factor and antikeratin/antifilaggrin antibodies for differentiating early rheumatoid arthritis from polymyalgia rheumaticaJoint Bone Spine, 2001Co-Authors: Valérie Devauchelle-pensec, Pierre Youinou, Alain Saraux, Paul Le GoffAbstract:
Abstract Objectives. To determine the prevalence and meaning of the Antiperinuclear Factor (APF) and antikeratin antibodies (AKA) in a group of patients with polymyalgia rheumatica (PMR) and/or giant cell arteritis (GCA) and to evaluate the usefulness of APF and AKA in distinguishing early rheumatoid arthritis (RA) from PMR/GCA in everyday clinical practice. Methods. Eighty patients with PMR and/or GCA were compared with 44 patients older than 50 years and admitted during the same period for evaluation of a possible diagnosis of RA. All the patients underwent a standardized evaluation including a physical examination and diagnostic investigations. Follow-up was 2 years. Results. Fourteen (17.5%) patients in the PMR/GCA group had APF in titers ⩾1/80, but only six (7.5%) had titers > 1/80. No significant differences were found between the subgroups with and without APF. None of these patients had detectable AKA. As compared to rheumatoid Factors (RF), APF and AKA showed poorer performances (sensitivity, 60%; specificity, 91%; efficiency, 77%) for diagnosing RA versus PMR/GCA. Combining RF and APF resulted in increased specificity (96%). Conclusions. The prevalence of APF in titers ⩾ 1/80 was high in PMR/GCA, but few patients (7.5%) had titers > 1/80. Presence of APF was not associated with specific features. All these patients were negative for AKA. RF has the best performance characteristics for diagnosing RA in older patients; RF combined with APF was more specific than RF alone.
Risk Factors for radiographic articular destruction of hands and wrists in rheumatoid arthritis.The Journal of rheumatology, 1999Co-Authors: H. Belghomari, Pierre Youinou, Alain Saraux, J. Allain, C. Guedes, P. Le GoffAbstract:
Objective. To carry out a cross sectional case-control study of the risk Factors for articular destruction in a large sample of patients with a long history of rheumatoid arthritis (RA). presupposing that the variables we measured were unrelated to the duration of disease. Methods. Each inpatient with RA admitted to our department from January 1, 1985, to December 31, 1995, underwent standard examination, laboratory tests, and hand roentgenograms. We carried out a radiographic cross sectional study on 287 of them. Radiographic evaluation was performed by the same observer (correlation coefficient 0.97) using the modified Sharp method. To investigate an association between articular destruction and prognostic variables, a matched analysis of the case-control data and calculation of the odds ratio (OR) with 95% confidence intervals (CI) were carried out. For each patient with severe articular destruction, patients hospitalized during the study period with the same disease duration but without severe articular destruction were included as controls. The sample size was chosen to show an OR > 2 (1 – alpha = 95%; 1 – beta = 80%). Results. The risk of articular joint destruction was higher in women than in men (OR 2.72, Cl 1.17-7.9, p < 0.023). whereas age at onset or the presence of HLA-DR4, Antiperinuclear Factor, or antikeratin antibodies was not sufficiently strongly associated with the process of articular destruction to be considered relevant prognostic markers. Conclusion. We conclude that female sex is significantly associated with a higher risk of articular destruction.
O. Meyer – One of the best experts on this subject based on the ideXlab platform.
British Journal of Rheumatology 1996;35:62O-624 DIAGNOSTIC VALUE OF ANTI-RA33 ANTIBODY, ANTTKERATIN ANTIBODY, ANTTPERINUCLEAR Factor AND ANTINUCLEAR ANTIBODY IN EARLY RHEUMATOID ARTHRITIS: COMPARISON WITH RHEUMATOID Factor, 2015Co-Authors: C. Cordonnier, O. Meyer, E. Palazzo, M. De Bandt, A. Elias, P. Nicaise, T. Halm, M. F. Kahn, G. ChatellierAbstract:
The goal of this prospective longitudinal study was to determine the serological profile of early rheumatoid arthritis (RA), and to test whether antikeratin antibody (AKA), Antiperinuclear Factor (API7), anti-RA33 antibody and antinuclear antibodies (ANA) had an additional diagnostic value when prescribed after rheumatoid Factor (RF)-detecting methods. Sixty-nine patients with early polyarthritis suggestive of RA, seen between 1991 and 1993, were included. Five autoantibodies (i.e. RF, AKA, APF, RA33, ANA) were looked for at regular intervals. After 24 months follow-up, patients were classified as having RA (n = 49), unclassified polyarthritis (UP; n = 15) or other rheumatic diseases. Among patients with early RA, the sensitivity of these marker
Autoantibodies predicting the outcome of rheumatoid arthritis: evaluation in two subsets of patients according to severity of radiographic damageAnnals of the rheumatic diseases, 1997Co-Authors: O. Meyer, A. Elias, Bernard Combe, K Benali, J Clot, Jacques Sany, Jean-françois EliaouAbstract:
OBJECTIVE Autoantibodies such as rheumatoid Factor (RF), antikeratin antibodies (AKA), Antiperinuclear Factor (APF), and anti-RA 33 antibodies are considered of value for the diagnosis of RA. The purpose of this study was to evaluate these autoantibodies as predictors of severe radiographic damage in rheumatoid arthritis (RA). PATIENTS AND METHODS Eighty six patients with RA (70 women, 16 men) fulfilling 1987 ACR criteria were selected from a cohort of 469 patients followed up since the first year of RA onset because they could be divided in two groups according to the severity of the radiographic damage. These 86 patients had a mean (SD) disease duration of eight (four) years: 43 patients had severe radiographic damage (Larsen score ⩾2) and 43 had limited radiographic damage (Larsen score RESULTS Patients with severe radiographic damage differed from those with limited radiographic damage in that they had higher RF (p=0.01), APF (p CONCLUSION These data suggest that the risk of severe radiographic damage in RA patients is higher when cutaneous nodules, HLA DRB1*04 or DRB1*01, and/or AKA are present. The other autoantibodies of diagnostic significance are of little help for predicting joint destruction.
DIAGNOSTIC VALUE OF ANTI-RA33 ANTIBODY, ANTIKERATIN ANTIBODY, Antiperinuclear Factor AND ANTINUCLEAR ANTIBODY IN EARLY RHEUMATOID ARTHRITIS: COMPARISON WITH RHEUMATOID FactorBritish journal of rheumatology, 1996Co-Authors: C. Cordonnier, O. Meyer, E. Palazzo, M. De Bandt, A. Elias, Nicaise P, T. Haim, G. ChatellierAbstract:
The goal of this prospective longitudinal study was to determine the serological profile of early rheumatoid arthritis (RA), and to test whether antikeratin antibody (AKA), Antiperinuclear Factor (APF), anti-RA33 antibody and antinuclear antibodies (ANA) had an additional diagnostic value when prescribed after rheumatoid Factor (RF)-detecting methods. Sixty-nine patients with early polyarthritis suggestive of RA, seen between 1991 and 1993, were included. Five autoantibodies (i.e. RF, AKA, APF, RA33, ANA) were looked for at regular intervals. After 24 months follow-up, patients were classified as having RA (n = 49), unclassified polyarthritis (UP; n = 15) or other rheumatic diseases. Among patients with early RA, the sensitivity of these markers was 40.8% for RF, 36.7% for AKA, 28.6% for APF and 28.6% for anti-RA33. Among RF-negative RA patients, 51.7% were positive for AKA, APF, anti-RA33 antibodies and/or ANA. Positivity of the three recent markers usually persisted throughout follow-up, whereas RF was lost by 58% of patients with early, RF-positive, treated RA. Using multivariate analysis, only latex, RF test and AKA or APF had an independent and statistically significant diagnostic value for early RA. Our data suggest that RF and AKA (or APF) should be concomitantly determined for diagnosis in patients with suspected early RA.
Kimmo Aho – One of the best experts on this subject based on the ideXlab platform.
Antifilaggrin antibodies in recent-onset arthritis.Scandinavian journal of rheumatology, 1999Co-Authors: Kimmo Aho, Pekka Kurki, T. Palosuo, M Lukka, Heikki Isomäki, Hannu Kautiainen, Von Essen RAbstract:
We evaluated the sensitivity and prognostic value of an enzyme-linked immunosorbent assay (ELISA) for the measurement of antifilaggrin antibodies (AFA), using filaggrin purified from human skin as an antigen. The AFA test was applied to a series of 306 patients with various recent-onset inflammatory joint diseases. The results were compared to those of the conventional immunofluorescence tests for antikeratin antibody (AKA) and Antiperinuclear Factor (APF) and of the rheumatoid Factor (RF) tests from a previous study. There was a very good agreement between the results of the tests for APF and AFA (kappa-value 0.79 in patients with peripheral poly/oligoarthritis). The agreement between the tests for AKA and AFA was significant but less pronounced (kappa-value 0.50). The AFA test detected 10/22 of the RF-negative erosive cases, particularly those with a large number of erosive joints. Thus, the test for AFA supplements RF in the prediction of erosiveness.
Antibody to Stratum Corneum (Antikeratin Antibody) and Antiperinuclear Factor: Markers for Progressive Rheumatoid ArthritisScandinavian journal of rheumatology, 1997Co-Authors: Pekka Kurki, R. Von Essen, T. Palosuo, K. Kaarela, Heikki Isomäki, Kimmo AhoAbstract:
The purpose of this study was to examine the relationship between circulating antibodies to stratum corneum (AKA) and Antiperinuclear Factors (APF) on one hand, and the x-ray progression of joint damage in chronic poly/oligoarthritis on the other hand.The analysis involved 133 patients with either rheumatoid or nonspecific arthritis derived from a cohort of 442 patients with recent onset arthritis. The patients were followed up for eight years with regular clinical, laboratory, and radiological evaluations. Radiographic evidence of joint destruction was quantitated by a radiographic index based on the Larsen grading.AKA and APF were detected, either at entry or at follow-up, in 26 and 54 patients, respectively. Seventy-six of the 133 patients had developed erosions. All AKA-positive patients had a rheumatoid Factor-positive erosive poly-arthritis. The presence of APF was also associated with a progressive arthritis although four APF-positive patients had a non-erosive disease. Neither AKA nor APF were abl…
Marker antibodies of rheumatoid arthritis: Diagnostic and pathogenetic implicationsSeminars in arthritis and rheumatism, 1994Co-Authors: Kimmo Aho, Timo Palosuo, Pekka KurkiAbstract:
Rheumatoid arthritis (RA) is associated with several autoantibodies specific enough to serve as diagnostic and prognostic markers. These include rheumatoid Factor (RF), antikeratin antibody (AKA), Antiperinuclear Factor (APF), and anti-RA33. The first three, and possibly also anti-RA33, may precede the onset of clinical RA. The prevalence of positive test reactions depends on the period between taking the specimen and onset of disease; when the period is short, the prevalence is nearly the same as in established disease. Thus, RA has a long asymptomatic period with broadening immunological activity. The assays for AKA and APF (and possibly also for anti-RA33), compared with RF testing, yielded greater specificity rather than the ability to define any subgroup with particularly severe disease. Used together, the above marker antibodies may form a new and more enlightened basis for defining seropositive RA. It is commonly believed that genetically mediated immune response plays an important role in the initiation of RA. However, the role of the major histocompatibility complex antigens may be in modulation of the inflammatory reaction in a later phase.